Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice

References

• Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007;41:568-73
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265-73
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60
   PubMed Web of Science ®Google Scholar
• Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients – recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110
   PubMed Web of Science ®Google Scholar
• Gothard P, Rogers TR. Voriconazole for serious fungal infections. Int J Clin Pract 2004;58:74-80
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products. Vfend Public Assessment Report. Summary of Product Characteristics. EMA, 2008. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/vfend/vfend.htm [Last accessed 9 November 2010]
   Google Scholar
• Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67:269-98
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008;30:403-11
   PubMed Web of Science ®Google Scholar
• Rogers TR, Frost S. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy. Br J Haematol 2009;144:629-41
   PubMed Web of Science ®Google Scholar
• Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009;53:541-51
   PubMed Web of Science ®Google Scholar
• Peman J, Salavert M, Canton E, et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag 2006;2:129-58
   PubMedGoogle Scholar
• Committee for Proprietary Medicinal Products. Vfend Public Assessment Report. Scientific Discussion. EMA, 2008. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/vfend/404901en6.pdf [Last accessed 9 November 2010]
   Google Scholar
• den Hollander JG, van Arkel C, Rijnders BJ, et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006;57:1248-50
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F, Nicolas-Arfelis JM, Rodriguez-Borregan JC, et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005;17:417-27
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Bohme A, Reichert D, et al. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol 2008;87:126-31
   PubMed Web of Science ®Google Scholar
• Federal Institute for Medicinal Products and Medical Devices (BfArM). Recommendations for the Planning, Execution and Evaluation of Post-Marketing Surveillance Studies (Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln – Empfehlungen zur Planung und Durchführung von Anwendungsbeobachtungen). Bonn, 12 November 1998. Available at: http://www.dzkf.de/heft/1999_1-2/AWBs.htm [Last accessed 9 November 2010]
   Google Scholar
• International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). MedDRA (Medical Dictionary for Regulatory Activities). Available at: http://meddramsso.com/mssoweb/index.htm [Last accessed 9 November 2010]
   Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66
   PubMed Web of Science ®Google Scholar
• Chandrasekar P. Selection criteria for antifungals: the right patients and the right reasons. Int J Antimicrob Agents 2006;27(Suppl. 1):17-20
   PubMedGoogle Scholar
• Tortorano AM, Kibbler C, Peman J, et al. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Buadi FK, McClune B. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy 2008;28:58-63
   PubMed Web of Science ®Google Scholar
• Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82(Suppl. 2):S105-17
   Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42
   PubMed Web of Science ®Google Scholar
• Gorski E, Esterly JS, Postelnick M, et al. An evaluation of hepatotoxicity with off-label oral treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother 2010 (in press)
   Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56(Suppl. 1):10-16
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
   PubMed Web of Science ®Google Scholar